Immune, Gut & Longevity
Best Peptides for Leaky Gut & Intestinal Permeability: Evidence (2026)
An evidence-first ranking of the peptides studied for the intestinal barrier — teduglutide, larazotide acetate, BPC-157 and KPV — separating one Grade-A drug for a different condition from failed, abandoned or preclinical-only 'leaky gut' claims.
teduglutide GLP-2larazotide leaky gutBPC-157 gut healingKPV peptidezonulin tight junctions
The quick verdict
No peptide has Grade A human evidence for reversing a generalized 'leaky gut.' We rank teduglutide, larazotide acetate, BPC-157 and KPV by the strength of their barrier-relevant evidence — and separate one drug for a different condition from failed, abandoned or preclinical-only claims.
- Best overall
- Teduglutide (GLP-2) — The only peptide with Grade A human RCT evidence on an absorptive/barrier-relevant endpoint — but it treats short bowel syndrome, NOT 'leaky gut.' Included to honestly anchor what Grade A intestinal-peptide evidence actually looks like.
- Best value
- Larazotide acetate — The only peptide rationally designed as a tight-junction/zonulin regulator and actually tested in humans — yet its pivotal permeability endpoint failed and its Phase 3 program was discontinued in 2022, so any 'value' is limited to celiac symptom relief.
- Best for Understanding the most-marketed 'gut healing' peptide and why its human evidence is absent
- BPC-157 — The largest, most mechanistically consistent preclinical gut record of the marketed peptides — but zero human efficacy RCTs for permeability, plus unapproved status and an all-times WADA ban. Deep animal data is not human proof.
How we evaluated
We ranked peptides by the strength and relevance of human evidence to intestinal-barrier endpoints, weighting completed, published human trials on permeability or absorption above preclinical models, and preclinical data above mechanism or anecdote. Human-trial pedigrees earned in other conditions (short bowel syndrome, celiac) are noted but do not become 'leaky gut' evidence. Grades are assigned honestly — only teduglutide reaches Grade A, and only for a condition other than leaky gut; we flag where marketing outruns proof.
- Human permeability/absorption evidence. Completed, published, controlled human trials on an intestinal-barrier or absorption endpoint — the highest weight. Only teduglutide qualifies, and only for short bowel syndrome.
- Barrier-mechanism relevance. Whether the peptide targets a validated barrier control point — tight-junction/zonulin regulation, trophic surface growth, NF-kB anti-inflammation, or mucosal repair.
- Preclinical depth & consistency. Depth, consistency and independent replication of rodent and cell-culture barrier/mucosal data.
- Safety & legal risk (2026). Neoplasia/growth-stimulation risk, pro-angiogenic and purity hazards, and FDA/WADA status relevant to anyone considering these agents.
Rating scale: 1-5 stars, in 0.5 increments, reflecting barrier-relevant evidence strength and safety — not general popularity. A high rating still means the human data is either for a different condition or absent.
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Teduglutide (GLP-2) | A | 4.5 | Anchoring what real Grade A intestinal-peptide evidence looks like — for short bowel syndrome, not leaky gut | FDA-approved (SBS-IF only); specialist-prescribed with REMS |
| 2 | Larazotide acetate | B | 3.0 | Understanding why even the purpose-built barrier peptide could not fix measured intestinal permeability | Unapproved everywhere; research-use-only |
| 3 | BPC-157 | C | 2.0 | Seeing why the most-marketed 'gut healing' peptide still lacks any human permeability evidence | Not FDA-approved; sold research-use-only |
| 4 | KPV | C | 1.5 | Appreciating the most disease-targeted anti-inflammatory mechanism — while recognizing it has never been tested in humans | Not FDA-approved; sold research-use-only |
Teduglutide (GLP-2)
The only Grade A human data here — but for short bowel syndrome, not leaky gut
Teduglutide ranks first because it is the only peptide on this list with rigorous human RCT efficacy on an absorptive, barrier-relevant endpoint — but it carries a large asterisk, because it does not treat 'leaky gut' at all. It is a recombinant GLP-2 analog, marketed as Gattex/Revestive, in which a single amino-acid substitution extends half-life to roughly two hours versus about seven minutes for native GLP-2. The FDA approved it in December 2012 for short bowel syndrome with intestinal failure, a defined surgical and anatomic intestinal-failure state. In the pivotal 24-week Phase 3 RCT, subcutaneous teduglutide at 0.05 mg/kg/day significantly increased the proportion of patients achieving clinically meaningful reductions in parenteral-support volume, and 48-week pediatric open-label data showed a meaningful share of children weaning completely off parenteral nutrition with median total energy absorption rising substantially. Mechanistically it binds GLP-2 receptors on enteroendocrine cells, subepithelial myofibroblasts and enteric neurons, releasing IGF-1, KGF and nitric oxide to drive crypt-cell proliferation, increase villus height and crypt depth, and raise mesenteric blood flow — physically enlarging absorptive surface rather than sealing leaks. Its inclusion here is to honestly anchor what Grade A intestinal-peptide evidence actually looks like, and to underline how far the popular 'leaky gut peptides' fall short of it.
Strengths
- The only peptide here with a rigorous, positive human Phase 3 RCT on an absorptive/barrier-relevant endpoint
- FDA-approved (Dec 2012) for short bowel syndrome with intestinal failure, with confirmatory pediatric absorption data
- Well-characterized trophic mechanism (GLP-2 receptor → IGF-1/KGF/NO) confirmed by mechanistic biopsies showing increased villus height and crypt depth
Weaknesses
- Does NOT treat 'leaky gut' — it is a trophic growth factor for patients who have lost intestinal length and depend on IV nutrition
- Trophic stimulation is double-edged: the label requires colonoscopic surveillance for intestinal (potentially neoplastic) growth, plus obstruction, biliary/pancreatic and fluid-overload warnings
- Using it as a general 'gut-barrier repair' agent is off-label and unsupported
- Best for
- Anchoring what real Grade A intestinal-peptide evidence looks like — for short bowel syndrome, not leaky gut
- Pricing
- FDA-approved (SBS-IF only); specialist-prescribed with REMS
Source: Jeppesen PB, et al., Gastroenterology 2012 (Phase 3 RCT)
Larazotide acetate
The one peptide designed to tighten junctions — but its permeability endpoint failed
Larazotide acetate ranks second because it is the single most relevant peptide to the leaky-gut thesis — the only agent rationally designed as a tight-junction regulator and zonulin antagonist, and the only one actually tested in humans for barrier function. It is an eight-amino-acid, orally administered, non-systemic, locally acting synthetic peptide meant to reduce gliadin- and cytokine-induced permeability by blunting junction opening and inhibiting MLCK-driven actin tension. Yet even it could not move a validated permeability measure. In its gluten-challenge RCT of 184 celiac patients, the primary permeability endpoint — the urinary lactulose-to-mannitol ratio — failed, with no significant difference versus placebo; only the lowest 1 mg dose reduced symptoms and blunted the anti-tTG IgA rise, an inverse dose-response that complicates interpretation. A later trial showed the 0.5 mg dose reduced signs and symptoms in celiac patients still symptomatic on a gluten-free diet, and a meta-analysis concluded it is safe and superior to placebo for symptoms during gluten challenge but is less likely to offer a definitive cure. Critically, its pivotal Phase 3 celiac program was discontinued in 2022 after interim analysis showed the treatment effect was too small. There is no approved larazotide product, and no evidence at all for a generalized 'leaky gut' indication outside celiac.
Strengths
- The only peptide here rationally designed as a tight-junction/zonulin regulator and actually tested in humans for barrier function
- Multiple placebo-controlled celiac RCTs plus a supportive meta-analysis for symptom relief during gluten challenge
- Non-systemic, locally acting oral peptide with adverse-event rates comparable to placebo and minimal systemic exposure
Weaknesses
- Failed its primary permeability endpoint (lactulose-to-mannitol ratio) versus placebo — the very mechanism it is sold on
- Pivotal Phase 3 celiac program discontinued in 2022 for an effect too small to reach significance; no approved product exists
- No evidence at all for a generalized 'leaky gut' indication outside celiac; benefit is limited to celiac symptoms
- Best for
- Understanding why even the purpose-built barrier peptide could not fix measured intestinal permeability
- Pricing
- Unapproved everywhere; research-use-only
Source: Kelly CP, et al., Aliment Pharmacol Ther 2013 (PMID 23163616)
BPC-157
Deep, consistent rodent gut record — zero human permeability trials; banned in sport
BPC-157 ranks third because, despite being one of the two peptides most aggressively marketed for 'gut healing' and 'leaky gut,' its evidence for intestinal permeability is entirely preclinical. It is a synthetic 15-amino-acid Body Protection Compound partial sequence. The preclinical literature is genuinely large and mechanistically consistent: in rodent and cell models BPC-157 upregulates tight-junction proteins including occludin, claudin and ZO-1, accelerates mucosal healing, reduces lesions in TNBS- and DSS-colitis models, and protects against NSAID-induced GI injury — a multi-pathway repair story spanning cytoprotection and angiogenesis. But critically, there are no published human RCTs for intestinal permeability or any gut indication; every efficacy claim for human 'leaky gut' is an extrapolation from animals, the textbook definition of Grade C, low-confidence evidence for human use. Regulatory status is unsettled: BPC-157 is not FDA-approved, was placed in 503A Category 2 in 2023, then removed in April 2026 after the original nominators withdrew — which is not approval, only a transitional gray zone — with a PCAC review set for July 23, 2026. It is prohibited at all times in sport under WADA category S0 with no Therapeutic Use Exemption, and any circulating dosing protocols are anecdotal and gray-market. Do not mistake breadth of preclinical data for human proof.
Strengths
- The largest and most mechanistically consistent preclinical gut record of the marketed peptides — tight-junction upregulation, mucosal healing, colitis and NSAID-injury protection
- Multi-pathway repair rationale (cytoprotection + angiogenesis) that is coherent across rodent and cell models
- Reported gastric-juice stability supports the rationale for oral use in luminal gut targets
Weaknesses
- No published human RCTs for intestinal permeability or any gut indication — all efficacy claims extrapolate from animals (Grade C)
- Prohibited at all times in sport under WADA S0; FDA-unapproved and in a 2026 compounding gray zone pending PCAC review
- Grey-market vials are frequently unverified for identity, purity and sterility
- Best for
- Seeing why the most-marketed 'gut healing' peptide still lacks any human permeability evidence
- Pricing
- Not FDA-approved; sold research-use-only
Source: BPC-157 gut preclinical aggregation (Palmetto Peptides, context)
KPV
Elegant PepT1-targeted anti-inflammation — but preclinical only, no human data
KPV ranks fourth because, while its preclinical anti-inflammatory and barrier-supportive data are strong and consistent, it has zero human efficacy evidence for intestinal permeability. KPV is the C-terminal Lys-Pro-Val tripeptide of alpha-MSH, retaining the parent hormone's anti-inflammatory signaling without melanocortin or pigmentary effects. In the foundational study, KPV was shown to be transported into intestinal epithelial and immune cells via the PepT1 di/tripeptide transporter — which is upregulated specifically in inflamed colon — and oral KPV reduced DSS- and TNBS-induced colitis with lower pro-inflammatory cytokine expression, inhibiting NF-kB and MAP-kinase signaling and lowering TNF-alpha, IL-1-beta and IL-6. Alpha-MSH itself protects cytokine-challenged Caco-2 intestinal monolayers, supporting a barrier-protective mechanism, and newer nanoparticle and prodrug delivery work continues to refine targeting. The PepT1-targeting story is pharmacologically elegant, because inflamed tissue absorbs more of the drug precisely where it is needed. But all of it is preclinical: there are no completed human efficacy trials for KPV in IBD, intestinal permeability, or 'leaky gut.' It is not FDA-approved, was among the peptides caught in the 2023 Category 2 action, and remains outside any positive compounding list as of mid-2026. Every human use is an extrapolation from animal and cell data, and no human safety profile exists.
Strengths
- Strong, consistent preclinical anti-inflammatory and barrier-supportive data across DSS and TNBS murine colitis models
- Disease-targeted mechanism: PepT1 upregulation in inflamed colon concentrates KPV where inflammation is, without melanocortin/pigmentary effects
- Supported by alpha-MSH barrier-protection data in cytokine-challenged Caco-2 monolayers and ongoing targeted-delivery research
Weaknesses
- No completed human efficacy trials for intestinal permeability, IBD or 'leaky gut' — all evidence is animal/cell (Grade C)
- No human safety profile exists; every human use is extrapolation from mice
- Falls under WADA S0 as a non-approved substance; FDA-unapproved and outside any positive compounding list
- Best for
- Appreciating the most disease-targeted anti-inflammatory mechanism — while recognizing it has never been tested in humans
- Pricing
- Not FDA-approved; sold research-use-only
Source: Dalmasso G, et al., Gastroenterology 2008 (PMID 18061177)
Feature comparison
| Feature | Teduglutide (GLP-2) | Larazotide acetate | BPC-157 | KPV |
|---|---|---|---|---|
| Human permeability/absorption trial | Phase 3 RCT (SBS) | Yes — LAMA endpoint failed | None | None |
| Barrier-mechanism relevance | Trophic surface growth | Tight-junction/zonulin regulation | Mucosal repair + tight junctions | PepT1-targeted NF-kB suppression |
| Preclinical depth | Extensive + mechanistic biopsies | Mechanistic + human RCTs | Extensive (rodent/in-vitro) | Replicated murine colitis + Caco-2 |
| Safety/legal flag | Neoplasia surveillance required | Non-systemic; Phase 3 discontinued | WADA S0; pro-angiogenic; gray zone | No human safety data; S0 |
Frequently asked
Is 'leaky gut' a real diagnosis I can treat with a peptide?
Increased intestinal permeability is a real, measurable physiological phenomenon, in which tight junctions between gut epithelial cells loosen and allow more paracellular leak. But 'leaky gut syndrome' is not a recognized medical diagnosis, and the popular claim that a generalized leaky gut broadly causes systemic disease lacks rigorous clinical proof. That framing problem matters before any peptide is discussed, because a peptide can only be judged against a defined clinical endpoint. As marketed, 'leaky gut' is not one — so no peptide has Grade A human evidence for 'treating leaky gut' as such. The most reliable evidence points upstream, to removing the driver of barrier injury.
Which peptide has the best human evidence for the gut barrier?
Teduglutide, a GLP-2 analog marketed as Gattex, has the only Grade A human RCT evidence in this space — but only for short bowel syndrome with intestinal failure, a defined surgical and anatomic condition, not for 'leaky gut.' In its pivotal 24-week Phase 3 trial it significantly increased the proportion of patients achieving clinically meaningful reductions in parenteral-nutrition support, and pediatric data show real gains in energy absorption. It works by physically enlarging absorptive surface — increasing villus height and crypt depth — rather than by 'sealing leaks.' Using it as a general gut-barrier repair agent is off-label and unsupported, and it carries growth-stimulation risks requiring colonoscopic surveillance.
Did larazotide work for intestinal permeability?
Not on the objective endpoint. Larazotide acetate is the one peptide rationally designed as a tight-junction regulator and zonulin antagonist, and it was tested in humans. But in its gluten-challenge RCT the primary permeability endpoint — the urinary lactulose-to-mannitol ratio — failed to beat placebo. Only the lowest 1 mg dose reduced symptoms, an inverse dose-response that complicates interpretation. A later trial showed symptom benefit in celiac patients still symptomatic on a gluten-free diet, and a meta-analysis found it safe and superior to placebo for symptoms during gluten challenge. But its pivotal Phase 3 celiac program was discontinued in 2022 for futility, and there is no approved larazotide product.
Does BPC-157 actually heal leaky gut in humans?
There is no human RCT evidence. BPC-157 is heavily marketed for 'gut healing,' and the preclinical literature is genuinely large and mechanistically consistent — in rodent and cell models it upregulates tight-junction proteins such as occludin, claudin and ZO-1, accelerates mucosal healing, and counters colitis and NSAID-induced injury. But every efficacy claim for human 'leaky gut' is an extrapolation from animals, the textbook definition of Grade C, low-confidence evidence for human use. BPC-157 is additionally not FDA-approved, sits in a 2026 regulatory gray zone, and is prohibited in sport at all times under WADA category S0. Do not mistake breadth of preclinical data for human proof.
Should I get a zonulin test to decide on peptides?
Generally no. Commercial zonulin ELISAs do not specifically measure zonulin, which is pre-haptoglobin-2. Independent work suggests these assays detect unrelated proteins such as properdin, with near-zero correlation to functional permeability tests — reported R values around 0.03 to 0.17. Treating a flawed biomarker with an unproven peptide compounds two uncertainties. The research-grade measure of permeability is the lactulose-to-mannitol ratio, which is a research tool rather than a routine clinical diagnostic. If you are worried about your gut barrier, the higher-yield step is identifying and removing a barrier insult — untreated celiac, NSAIDs, alcohol, dysbiosis — with a qualified clinician, not chasing a test-and-peptide loop.
What is the safest, best-supported approach to a 'leaky' gut barrier?
A root-cause, functional-medicine lens puts the highest-yield interventions upstream of any peptide. The controlled evidence most consistently supports removing the driver of barrier injury: strict gluten avoidance in celiac disease — the one setting where increased permeability reliably normalizes — minimizing NSAIDs and alcohol, and addressing dysbiosis. That is where the controlled evidence actually points, whereas peptides marketed specifically for leaky gut are either a failed and abandoned human program or preclinical-only. Any decision about an unapproved or investigational peptide must be made with a licensed clinician; grey-market 'research use only' vials are frequently unverified for identity, purity and sterility, so 'research use only' covers sale, not safe human use.